Histopathological phenotyping of cancers in PTEN Hamartoma Tumor Syndrome for improved recognition: A single‐center study
International Journal of Cancer · 2024
DOI: 10.1002/ijc.35049 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Ane J Schei-Andersen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: PTEN Phosphohydrolase, Hamartoma Syndrome, Multiple. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HORIZON EUROPE Marie Sklodowska-Curie Actions, PTEN Research Foundation, PTEN Research.
Abstract (Originalsprache)
PTEN hamartoma tumor syndrome (PHTS) has a broad clinical spectrum including various benign and malignant tumors at varying age of diagnosis. Many patients remain unrecognized, unaware of their increased cancer risk. We aimed to describe the cancer spectrum, age of onset and histopathological cancer characteristics to assess whether specific cancer characteristics could improve PHTS recognition. Genetic testing results and pathology reports were collected for patients tested for germline PTEN variants between 1997 and 2020 from the diagnostic laboratory and the Dutch nationwide pathology databank (Palga). The cancer spectrum and age of onset were assessed in patients with (PTENpos) and without (PTENneg) a germline PTEN variant. Histopathological cancer characteristics were assessed in a nested cohort. 341 PTENpos patients (56% females) and 2882 PTENneg patients (66% females) were included. PTENpos patients presented mostly with female breast (BC, 30%), endometrial (EC, 6%), thyroid (TC, 4%) or colorectal cancer (4%). PTENpos were significantly younger at cancer onset (43 vs. 47 years) and had more often (46% vs. 18%) a second BC than PTENneg. PTEN detection rates were highest for BC
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
- Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Pediatric Neurology, Radboud University Medical Center, Amalia Children's Hospital, Nijmegen, The Netherlands.
- European Reference Network Genetic Tumour Risk Syndromes (ERN GENTURIS).
ORCID-Profile: Ane J Schei-Andersen, Linda A J Hendricks, Rachel S van der Post, Arjen R Mensenkamp, Janneke H M Schuurs-Hoeijmakers, Nicoline Hoogerbrugge, Janet R Vos
Förderung
- HORIZON EUROPE Marie Sklodowska-Curie Actions
- PTEN Research Foundation
- PTEN Research
Zitieren
APA
Schei-Andersen, A. J., Hendricks, L. A. J., van der Post, R. S., Mensenkamp, A. R., Schieving, J., PTEN Study Group, Schuurs-Hoeijmakers, J. H. M., Hoogerbrugge, N., & Vos, J. R. (2024). Histopathological phenotyping of cancers in PTEN Hamartoma Tumor Syndrome for improved recognition: A single‐center study. International Journal of Cancer. https://doi.org/10.1002/ijc.35049
Vancouver
Schei-Andersen AJ, Hendricks LAJ, van der Post RS, Mensenkamp AR, Schieving J, PTEN Study Group, et al. Histopathological phenotyping of cancers in PTEN Hamartoma Tumor Syndrome for improved recognition: A single‐center study. International Journal of Cancer. 2024. doi:10.1002/ijc.35049
BibTeX
@article{ScheiAndersen2024,
author = {Schei-Andersen, Ane J and Hendricks, Linda A J and van der Post, Rachel S and Mensenkamp, Arjen R and Schieving, Jolanda and PTEN Study Group, PTEN Study Group and Schuurs-Hoeijmakers, Janneke H M and Hoogerbrugge, Nicoline and Vos, Janet R},
title = {Histopathological phenotyping of cancers in PTEN Hamartoma Tumor Syndrome for improved recognition: A single‐center study},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.35049}
}
EUVIMED